Table 1 Multivariable analysis of factors associated with intravenous macrolide treatment

Gender (male)

0.79 (0.55–1.13), p = 0.2

Age

1.01 (0.99–1.03), p = 0.1

Congestive cardiac failure

0.83 (0.51–1.35), p = 0.5

Liver disease

0.94 (0.44–2.00), p = 0.9

Stroke

1.23 (0.68–2.22), p = 0.5

COPD

0.80 (0.52–1.23), p = 0.3

Diabetes

1.06 (0.63–1.80), p = 0.8

Smoking status

1.04 (0.71–1.52), p = 0.8

CURB-65 score

1.13 (0.90–1.41), p = 0.3

Temperature

1.07 (0.89–1.29), p = 0.5

Pulse rate

1.0 (0.99–1.01), p = 0.4

Prior statin use

1.11 (0.71–1.75), p = 0.7

Antiplatelets

1.01 (0.65–1.56), p = 0.9

ACE inhibitors/ARBs

0.90 (0.56–1.45), p = 0.7

Beta-lactam co-administration

0.89 (0.56–1.41), p = 0.6

Corticosteroid use

0.90 (0.49–1.66), p = 0.7

Sodium level

0.99 (0.95–1.03), p = 0.5

Haemoglobin

1.00 (0.99–1.01), p = 0.4

White cell count

1.01 (0.99–1.02), p = 0.3

Platelet count

1.00 (0.99–1.00), p = 0.8

Albumin

1.0 (0.49–1.66), p = 0.7

Multilobar radiographic changes

1.14 (0.73–1.79), p = 0.6

Antibiotic treatment prior to admission

1.67 95% CI 0.96–2.92), p = 0.08